HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fleming stock, debt offering

This article was originally published in The Rose Sheet

Executive Summary

Texas-based consumer product distributor announces offering of 8 mil. shares of common stock and $200 mil. in senior notes, with estimated net proceeds of $385 mil. Proceeds will be used to fund the firm's $390 mil. purchase of Core-Mark International, a "piece-pick" distributor to convenience stores operating primarily in western North America. With the acquisition, Fleming's total annualized sales will top $19 mil. Fleming recently announced a nearly $20 mil. fourth quarter charge related to the Kmart bankruptcy (1"The Rose Sheet" Feb. 18, 2002, In Brief)...

You may also be interested in...

Fleming takes fourth quarter charge

Distributor Fleming Companies records $19.8 mil. pre-tax charge in fourth quarter related to Kmart bankruptcy reorganization, company says. Charge "represents reserves against Fleming's total $37.8 mil. in pre-petition receivables from Kmart and against certain slow-moving Kmart-related inventory," Fleming adds, noting it intends to pursue collection of all money it is owed through bankruptcy court. Distribution segment sales increased 31% in the quarter on a 12-week comparable basis, and earnings before interest, taxes, depreciation and amortization were up 20% to $137.9 mil. Fleming is exclusive foods and consumable goods distributor to Kmart and distributes for Procter & Gamble and Dial among others. Kmart filed for bankruptcy in January (1"The Rose Sheet" Jan. 28, 2002, p. 7)...

Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts